Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2137 views | HTML 2899 views | ?
Paola Corazao-Rozas1,2,3,*, Pierre Guerreschi1,2,3,*, Fanny André1,2,3, Pierre-Elliott Gabert1,2,3, Steve Lancel4, Salim Dekiouk1,2,3, Delphine Fontaine1,2,3, Meryem Tardivel6, Ariel Savina7, Bruno Quesnel1,2,3, Laurent Mortier1,2,3, Philippe Marchetti1,2,3,5,#, Jérome Kluza1,2,3,#
1University Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France
2Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille, France
3SIRIC OncoLille, Lille, France
4University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, Lille, France
5Centre de Bio-Pathologie, Plate-forme de Biothérapie, Banque de Tissus, CHRU Lille, Lille, France
6Bioimaging Center, Lille Nord de France-Campus HU, Université de Lille 2, Lille, France
7Institut Roche, Boulogne-Billancourt, France
*These authors contributed equally to this work
#These authors shared equally co-ownership to this work
Jérome Kluza, email: [email protected]
Philippe Marchetti, email: [email protected]
Keywords: vemurafenib, cobimetinib, BRAF, Ca2+ uptake, melanoma
Received: November 05, 2015 Accepted: February 05, 2016 Published: February 29, 2016
Although MAPK pathway inhibitors are becoming a promising anticancer strategy, they are insufficient to fully eliminate cancer cells and their long-term efficacy is strikingly limited in patients with BRAF-mutant melanomas. It is well established that BRAF inhibitors (BRAFi) hamper glucose uptake before the apparition of cell death. Here, we show that BRAFi induce an extensive restructuring of mitochondria including an increase in mitochondrial activity and biogenesis associated with mitochondrial network remodeling. Furthermore, we report a close interaction between ER and mitochondria in melanoma exposed to BRAFi. This physical connection facilitates mitochondrial Ca2+ uptake after its release from the ER. Interestingly, Mfn2 silencing disrupts the ER–mitochondria interface, intensifies ER stress and exacerbates ER stress-induced apoptosis in cells exposed to BRAFi in vitro and in vivo. This mitochondrial control of ER stress-mediated cell death is similar in both BRAF- and NRAS-mutant melanoma cells exposed to MEK inhibitors. This evidence reinforces the relevance in combining MAPK pathway inhibitors with mitochondriotropic drugs to improve targeted therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.